English (international)
Eesti
Български
Deutsch
Français
Español (Latinoamérica)
Polski
Magyar
Română
Compugen Ltd
Suletud
1.83
Ülevaade
Aktsiahinna muutus
24h
Min
1.83
Max
1.86
Sissetulek | 2.6M -7.3M |
|---|---|
Müük | -31M 2.6M |
Aktsiakasum | -0.08 |
Kasumimarginaal | -283.978 |
EBITDA | -8.5M |
Soovitused | Tugev "osta" hinnang |
|---|---|
12 kuu keskmine prognoos | +118.58 upside |
Järgmine tulemuste avaldamine | 5. nov 2024 |
|---|
Turukapital | 47M 640M |
|---|---|
Eelmine avamishind | 1.83 |
Eelmine sulgemishind | 1.83 |
Tehniline skoor
By Trading Central
Kindlus
Strong Bearish Evidence
Compugen Ltd Graafik
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Compugen Ltd Prognoos
Hinnasiht
By TipRanks
118.58% tõus
12 kuu keskmine prognoos
Keskmine 4 USD 118.58%
Kõrge 4 USD
Madal 4 USD
Põhineb 3 Wall Streeti analüütiku instrumendi Compugen Ltd 12 kuu hinnasihil - viimase 3 kuu andmed.
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
EBITDA
Ärikasum
$
Ettevõttest Compugen Ltd
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
